• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Gold Rises Over 1%; Elys Game Technology Shares Spike Higher

    12/27/22 2:31:10 PM ET
    $ACER
    $ELYS
    $HPK
    $HTGM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology
    Get the next $ACER alert in real time by email

    U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining around 175 points on Tuesday.

    The Dow traded up 0.10% to 33,237.71 while the NASDAQ fell 1.29% to 10,362.21. The S&P 500 also fell, dropping, 0.48% to 3,826.23.

    Check This Out: Top 5 Industrials Stocks That May Rally


    Leading and Lagging Sectors


    Energy shares rose by 0.9% on Tuesday. Meanwhile, top gainers in the sector included Mammoth Energy Services, Inc. (NASDAQ:TUSK), up 14%, and HighPeak Energy, Inc. (NASDAQ:HPK), up 8%.


    In trading on Tuesday, consumer discretionary shares fell by 0.7%.


    Top Headline

     

    The S&P CoreLogic Case-Shiller 20-city home price index increased by 8.6% year-over-year in October, which is the least since October 2020.

     

    Equities Trading UP

     

    • KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) shares shot up 17% to $5.97. KalVista Pharmaceuticals reported a $58 million registered direct offering.
    • Shares of Elys Game Technology, Corp. (NASDAQ:ELYS) got a boost, shooting 131% to $0.4030 after the company and Cloakbook were granted a license to commence sportsbook operations in Washington, D.C.
    • HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) shares were also up, gaining 50% to $4.6499. HTG Molecular Diagnostics announced closing of a $10 million public offering.

     

    Equities Trading DOWN

    • Acer Therapeutics Inc. (NASDAQ:ACER) shares tumbled 33% to $2.50. Acer Therapeutics and Relief Therapeutics reported the FDA approval of OLPRUVA for patients with urea cycle disorders.
    • Shares of Tuesday Morning Corporation (NASDAQ:TUEM) were down 44% to $0.8624 after the company announced it will voluntarily delist from the Nasdaq Capital Market.
    • Pingtan Marine Enterprise Ltd. (NASDAQ:PME) was down, falling 58% to $0.1269. Pingtan Marine Enterprise announced receipt of Nasdaq notification letter.


    Also Check This Out: $5.5 Million Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying


    Commodities

    In commodity news, oil traded up 1.8% to $80.95 while gold traded up 1.2% at $1,825.50.


    Silver traded up 1.5% to $24.275 on Tuesday while copper rose 1.9% to $3.8805.

     



    Euro zone


    European shares were mostly higher today. The eurozone’s STOXX 600 gained 0.13%, while Spain’s IBEX 35 Index rose 0.01%. The German DAX gained 0.39%, French CAC 40 rose 0.70% and Italy’s FTSE MIB Index fell 0.09%.

     


    Asia Pacific Markets


    Asian markets closed higher on Tuesday, with the Japan’s Nikkei gaining 0.16% and China’s Shanghai Composite Index rose 0.98%.


    Retail sales in Japan climbed 2.6% from a year earlier in November, while unemployment rate declined to 2.5% in November. Japanese housing starts fell by 1.4% year-over-year in November, missing market expectations for a 1.5% rise. China revised its GDP growth rate to 8.4% for 2021, compared to 8.1% previously, the National Bureau of Statistics said. Profits earned by Chinese industrial firms dropped on an annual basis by 3.6% to 7.7 trillion yuan during the January-November period.

     

    Economics

     

    • The US trade deficit in goods shrank by 15.6% from a month ago to $83.3 billion in November, recording the smallest gap since December 2020.
    • The S&P CoreLogic Case-Shiller 20-city home price index increased by 8.6% year-over-year in October, which is the least since October 2020.
    • The FHFA house price index came in unchanged from a month ago during October.
    • Wholesale inventories in the US increased by 1.0% month-over-month to $933.6 billion in November compared to a revised 0.6% growth in the previous month.

     

    Now Read This: This Analyst With 88% Accuracy Rate Boosts PT On Nike; Here Are 5 Stock Picks For Last Week From Benzinga's Most Accurate Analysts


    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 102,247,570 cases with around 1,116,090 deaths. India confirmed a total of at least 44,678,540 cases and 530,690 deaths, while France reported over 39,159,750 COVID-19 cases with 161,150 deaths. In total, there were at least 662,415,920 cases of COVID-19 worldwide with more than 6,687,740 deaths.

    Get the next $ACER alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACER
    $ELYS
    $HPK
    $HTGM

    CompanyDatePrice TargetRatingAnalyst
    KalVista Pharmaceuticals Inc.
    $KALV
    1/9/2026$32.00 → $35.00Buy
    Needham
    KalVista Pharmaceuticals Inc.
    $KALV
    1/6/2026$28.00 → $32.00Buy
    Needham
    HighPeak Energy Inc.
    $HPK
    10/14/2025$12.00Buy
    Roth Capital
    HighPeak Energy Inc.
    $HPK
    4/7/2025$10.00Underperform
    BofA Securities
    KalVista Pharmaceuticals Inc.
    $KALV
    1/31/2025$19.00Mkt Outperform
    JMP Securities
    KalVista Pharmaceuticals Inc.
    $KALV
    1/7/2025$30.00Buy
    TD Cowen
    KalVista Pharmaceuticals Inc.
    $KALV
    12/18/2024$22.00Buy
    BofA Securities
    HighPeak Energy Inc.
    $HPK
    5/23/2024$10.00 → $13.00Sell → Hold
    Truist
    More analyst ratings

    $ACER
    $ELYS
    $HPK
    $HTGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Operations Officer Arif Bilal

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    1/21/26 4:11:45 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Commercial Officer Sweeny Nicole

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    1/21/26 4:11:12 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Piekos Brian

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    1/21/26 4:10:39 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACER
    $ELYS
    $HPK
    $HTGM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for OLPRUVA issued to ACER THERAPEUTICS INC

    Submission status for ACER THERAPEUTICS INC's drug OLPRUVA (ORIG-1) with active ingredient SODIUM PHENYLBUTYRATE has changed to 'Approval' on 12/22/2022. Application Category: NDA, Application Number: 214860, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/23/22 1:58:04 PM ET
    $ACER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACER
    $ELYS
    $HPK
    $HTGM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ACER
    $ELYS
    $HPK
    $HTGM
    SEC Filings

    View All

    $ACER
    $ELYS
    $HPK
    $HTGM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ACER
    $ELYS
    $HPK
    $HTGM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Mammoth Announces Fourth-Quarter and Full-Year 2025 Conference Call

    OKLAHOMA CITY, Feb. 5, 2026 /PRNewswire/ -- Mammoth Energy Services, Inc. (NASDAQ:TUSK) ("Mammoth" or the "Company") will host a conference call on Friday, March 6, 2026, to discuss the Company's results for the fourth quarter and full year ended December 31, 2025. The conference call will begin at 11:00 a.m. Eastern Time (10:00 a.m. Central Time). Prior to the call, the Company will issue a press release announcing the results, which will also be available in the Investor Relations section of the Mammoth website. The call will be webcast live and can be accessed through the C

    2/5/26 4:30:00 PM ET
    $TUSK
    Oilfield Services/Equipment
    Energy

    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted six newly-hired employees inducement options to purchase an aggregate of 96,750 shares of KalVista common stock on February 1, 2026 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the first day a closing price is reported following the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each cas

    2/3/26 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results

    Approximately $35 million and $49 million unaudited global net product revenue of EKTERLY (sebetralstat) for the fourth quarter and full year 2025, respectively 1,318 patient start forms received in the US through December, reflecting continued rapid adoption as first and only oral on-demand treatment for hereditary angioedema (HAE); Germany launch also demonstrating strong early adoption Partnered with Multicare Pharma to commercialize sebetralstat in Latin America; third commercial partnership in 10 months KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided its preliminary fourth quarter and full year ended December 31, 2025 unaudited global net product revenue results and

    1/8/26 4:05:00 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by KalVista Pharmaceuticals Inc.

    S-8 - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

    1/26/26 5:00:38 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

    1/8/26 4:47:09 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by KalVista Pharmaceuticals Inc.

    SCHEDULE 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    12/30/25 4:28:56 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham reiterated coverage on KalVista Pharmaceuticals with a new price target

    Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $35.00 from $32.00 previously

    1/9/26 7:49:25 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham reiterated coverage on KalVista Pharmaceuticals with a new price target

    Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $32.00 from $28.00 previously

    1/6/26 7:58:35 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital resumed coverage on HighPeak Energy with a new price target

    Roth Capital resumed coverage of HighPeak Energy with a rating of Buy and set a new price target of $12.00

    10/14/25 8:50:01 AM ET
    $HPK
    Oil & Gas Production
    Energy

    Director Amron Arthur H bought $18,900 worth of shares (10,000 units at $1.89), increasing direct ownership by 21% to 57,135 units (SEC Form 4)

    4 - MAMMOTH ENERGY SERVICES, INC. (0001679268) (Issuer)

    12/15/25 5:04:40 PM ET
    $TUSK
    Oilfield Services/Equipment
    Energy

    Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $235,500 worth of shares (25,000 units at $9.42) (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    4/11/25 5:22:07 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $1,498,661 worth of shares (161,700 units at $9.27) (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    2/14/25 7:45:15 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACER
    $ELYS
    $HPK
    $HTGM
    Financials

    Live finance-specific insights

    View All

    Mammoth Announces Fourth-Quarter and Full-Year 2025 Conference Call

    OKLAHOMA CITY, Feb. 5, 2026 /PRNewswire/ -- Mammoth Energy Services, Inc. (NASDAQ:TUSK) ("Mammoth" or the "Company") will host a conference call on Friday, March 6, 2026, to discuss the Company's results for the fourth quarter and full year ended December 31, 2025. The conference call will begin at 11:00 a.m. Eastern Time (10:00 a.m. Central Time). Prior to the call, the Company will issue a press release announcing the results, which will also be available in the Investor Relations section of the Mammoth website. The call will be webcast live and can be accessed through the C

    2/5/26 4:30:00 PM ET
    $TUSK
    Oilfield Services/Equipment
    Energy

    Mammoth Energy Services, Inc. Announces Sale of Engineering Business

    Sales Price of $30.0 million; Further Expands Deployment Opportunities OKLAHOMA CITY, Dec. 2, 2025 /PRNewswire/ -- Mammoth Energy Services, Inc. (NASDAQ:TUSK) ("Mammoth" or the "Company") today announced that its subsidiary, Mammoth Energy Partners LLC, has completed a sale of all equity interests in its wholly owned subsidiary, Aquawolf LLC ("Aquawolf"), to Qualus, LLC for an aggregate sales price of $30.0 million, advancing the Company's ongoing transformation and portfolio optimization initiatives. Aquawolf's revenue grew from $12.1 million in 2022 to $17.3 million in 2024,

    12/2/25 4:30:00 PM ET
    $TUSK
    Oilfield Services/Equipment
    Energy

    KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results

    US launch of EKTERLY® gaining strong momentum with $13.7 million in net product revenue for the third quarter 937 patient start forms received through October, reflecting rapid adoption as first and only oral on-demand treatment for hereditary angioedema (HAE) Launched EKTERLY in Germany with initial orders signaling encouraging demand $309M in cash expected to fund the Company through profitability Management to host conference call Tuesday, November 11th at 8:30 a.m. ET KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided an operational update and reported financial results for the third quarter ended September 30, 2025. "The US launch of EKTERLY is progressing with si

    11/10/25 4:30:00 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACER
    $ELYS
    $HPK
    $HTGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

    SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    11/14/24 4:00:06 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

    SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    11/14/24 3:57:49 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by KalVista Pharmaceuticals Inc.

    SC 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    11/14/24 12:02:33 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACER
    $ELYS
    $HPK
    $HTGM
    Leadership Updates

    Live Leadership Updates

    View All

    KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the appointments of Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer, effective October 6, 2025. "I am pleased to welcome Bilal and Linea to our leadership team as we advance the global launch of EKTERLY," said Ben Palleiko, Chief Executive Officer of KalVista. "Their respective expertise in operations and human resources will be instrumental as we deliver on our commitment to people living with HAE." "I am excited to join KalVista and collaborate with such a talented team," said Mr. Arif. "This is a pivotal time for EKTERLY, and I am focused on strengthening the operational framework to ensure pe

    10/6/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the appointment of Bethany L. Sensenig to its Board of Directors, effective as of October 1, 2025. Ms. Sensenig was also appointed a member of the Audit Committee of the Board. In connection with Ms. Sensenig's appointment to the Audit Committee, Nancy Stuart will transition off the Audit Committee but remains a member of the Board and continues to serve on the Nominating and Corporate Governance Committee of the Board. The Board also approved Ms. Stuart's appointment to the Compensation Committee of the Board. "I am pleased to welcome Bethany to the Board of Directors of KalVista. Her extensive financial and operational experti

    10/2/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HighPeak Energy, Inc. Announces CEO Transition

    FORT WORTH, Texas, Sept. 16, 2025 (GLOBE NEWSWIRE) -- HighPeak Energy, Inc. ("HighPeak" or the "Company") (NASDAQ:HPK) today announced that the Board of Directors (the "Board") and Mr. Jack Hightower, current Chief Executive Officer and Chairman of the Board, have agreed that Mr. Hightower will retire from his positions with the Company, including as Chief Executive Officer, a director and Chairman of the Board. The Company also announced that Michael L. Hollis, current President of the Company and a member of the Board, has been appointed Interim Chief Executive Officer of the Company, effective immediately. Mr. Hollis has served as President of HighPeak and a member of the Board since

    9/16/25 5:50:00 AM ET
    $FANG
    $HPK
    Oil & Gas Production
    Energy